Ireland-headquartered drugmaker Shire (LSE: SHP) says it has filed law suits in the US District Court for the District of New Jersey against each of privately-held US generic drugmaker Amneal Pharmaceuticals and Sandoz Inc, the US generics subsidiary of Swiss drug major Novartis (NOVN: VX) for infringement of certain of Shire's attention-deficit hyperactivity disorder (ADHA) treatment Vyvanse (lisdexamfetamine dimesylate) patents.
The law suits were initiated in response to Abbreviated New Drug Applications filed by Amneal and Sandoz seeking US Food and Drug Administration approval to market and sell generic versions of all currently approved doses of Vyvanse.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze